Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Biology
  • View Item
  • Home
  • ICR Divisions
  • Cancer Biology
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Thumbnail
View/Open
Accepted version (766.3Kb)
Publication Date
2018-06
ICR Author
Harrington, Kevin
Melcher, Alan
Author
Comins, C
Simpson, GR
Rogers, W
Relph, K
Harrington, K
Melcher, A
Roulstone, V
Kyula, J
Pandha, H
Type
Journal Article
Metadata
Show full item record
Abstract
There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress highlights the huge clinical potential of this treatment modality, and the focus is now combining these agents with conventional anticancer treatments or agents that enhance viral replication, and thereby oncolysis, in the tumour microenvironment. We evaluated the combination of reovirus with rapamycin in B16F10 cell, a murine model of malignant melanoma, based on potential mechanisms by which mTOR inhibitors might enhance viral oncolysis. Rapamycin was not immunomodulatory in that it had no effect on the generation of an antireovirus-neutralising antibody response in C57/black 6 mice. The cell cycle effects of reovirus (increase G0/G1 fraction) were unaffected by concomitant or sequential exposure of rapamycin. However, rapamycin attenuated viral replication if given prior or concomitantly with reovirus and similarly reduced reovirus-induced apoptotic cell death Annexin V/PI and caspase 3/7 activation studies. We found clear evidence of synergistic antitumour effects of the combination both in vitro and in vivo, which was sequence dependent only in the in vitro setting. In conclusion, we have demonstrated synergistic antitumour efficacy of reovirus and rapamycin combination.
URL
https://repository.icr.ac.uk/handle/internal/1676
Collections
  • Cancer Biology
  • Radiotherapy and Imaging
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1038/s41417-018-0011-8
Research team
Targeted Therapy
Translational Immunotherapy
Language
eng
Date accepted
2017-08-31
License start date
2018-06
Citation
Cancer Gene Ther, 2018, 25 (5-6), pp. 148 - 160

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.